There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IMV (IMV) and Sangamo Biosciences (SGMO) with bullish sentiments.
IMV (IMV)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on IMV today and set a price target of $11.50. The company’s shares closed last Monday at $2.83.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -3.0% and a 38.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
IMV has an analyst consensus of Strong Buy, with a price target consensus of $8.30, implying a 176.7% upside from current levels. In a report issued on November 25, Oppenheimer also initiated coverage with a Buy rating on the stock with a C$9.00 price target.
See today’s analyst top recommended stocks >>
Sangamo Biosciences (SGMO)
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Sangamo Biosciences today and set a price target of $16.00. The company’s shares closed last Monday at $11.66.
According to TipRanks.com, Chattopadhyay is a 4-star analyst with an average return of 4.3% and a 48.6% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Audentes Therapeutics, and Precision BioSciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sangamo Biosciences with a $13.50 average price target, implying a 14.9% upside from current levels. In a report released today, Cowen & Co. also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.